STOK Stock Price, Stoke Therapeutics Inc Quote, Chart

Market Summary

USD11.00-1.05

Delayedas of 22 Apr 2024, 12:59 pm

-8.71%

STOK Alerts

3 major insider sales recently.

STOK Stock Price

View Fullscreen

STOK RSI Chart

STOK Valuation

Market Cap

558.0M

Price/Earnings (Trailing)

-5.33

Price/Sales (Trailing)

63.55

Price/Free Cashflow

-6.75

STOK Price/Sales (Trailing)

STOK Profitability

Return on Equity

-65.62%

Return on Assets

-45.85%

Free Cashflow Yield

-14.82%

STOK Fundamentals

STOK Revenue

Revenue (TTM)

8.8M

Rev. Growth (Yr)

-14.27%

Rev. Growth (Qtr)

-15.3%

STOK Earnings

Earnings (TTM)

-104.7M

Earnings Growth (Yr)

-5.08%

Earnings Growth (Qtr)

-9.84%

Breaking Down STOK Revenue

52 Week Range

12.05

(Low)(High)

Last 7 days

-5.6%

Last 30 days

101.2%

Last 90 days

144.4%

Trailing 12 Months

41.6%

How does STOK drawdown profile look like?

STOK Financial Health

Current Ratio

6.99

STOK Investor Care

Shares Dilution (1Y)

4.88%

Diluted EPS (TTM)

-2.38

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	14.6M	12.6M	10.7M	8.8M
2022	0	0	0	12.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Stoke Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 17, 2024	skorpios trust	sold	-41,760,000	11.6	-3,600,000	-
Apr 01, 2024	ticho barry	acquired	265	0.6	442	chief medical officer
Apr 01, 2024	ticho barry	sold	-124,684	13.2277	-9,426	chief medical officer
Apr 01, 2024	nash huw m.	sold	-811,212	13.2272	-61,329	coo & cbo
Apr 01, 2024	nash huw m.	acquired	20,000	0.4	50,000	coo & cbo
Mar 28, 2024	allan jonathan	sold	-67,667	13.2009	-5,126	general counsel & corp sec
Mar 19, 2024	tulipano stephen j	sold	-25,101	6.0986	-4,116	cfo
Mar 19, 2024	ticho barry	sold	-25,101	6.0986	-4,116	chief medical officer
Mar 19, 2024	nash huw m.	sold	-25,101	6.0986	-4,116	coo & cbo
Mar 19, 2024	kaye edward m. md	sold	-67,999	6.0986	-11,150	ceo

Which funds bought or sold STOK recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 05, 2024	LOS ANGELES CAPITAL MANAGEMENT LLC	unchanged	-	512,998	840,470	-%
Apr 05, 2024	GAMMA Investing LLC	new	-	1,580	1,580	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	new	-	26.00	26.00	-%
Mar 21, 2024	HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND	unchanged	-	315,876	1,258,720	-%
Mar 11, 2024	VANGUARD GROUP INC	added	1.09	2,246,210	8,671,120	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	2,052	14,128,400	14,637,900	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	reduced	-0.41	17,878	72,120	-%
Feb 27, 2024	Beaird Harris Wealth Management, LLC	sold off	-100	-150	-	-%
Feb 16, 2024	PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO	added	5.8	26,909	90,909	-%
Feb 16, 2024	PRICE T ROWE ASSOCIATES INC /MD/	unchanged	-	39,000	157,000	-%

Are Funds Buying or Selling STOK?

Are funds buying STOK calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own STOK

No. of Funds

STOK Alerts

3 major insider sales recently.

Unveiling Stoke Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 18, 2024	skorpios trust	-	6,905,121	SC 13D/A
Feb 26, 2024	cowen financial products llc	5.77%	2,276,106	SC 13G
Feb 26, 2024	cowen financial products llc	8.3%	3,721,659	SC 13G/A
Feb 14, 2024	lynx1 capital management lp	6.6%	2,956,918	SC 13G/A
Feb 14, 2024	rtw investments, lp	9.3%	4,131,045	SC 13G/A
Feb 14, 2024	redmile group, llc	5.9%	2,625,506	SC 13G/A
Feb 09, 2024	morgan stanley	7.5%	3,358,375	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Nov 06, 2023	lynx1 capital management lp	6.0%	2,664,158	SC 13G
Feb 14, 2023	rtw investments, lp	9.8%	3,870,981	SC 13G/A

Recent SEC filings of Stoke Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 18, 2024	4	Insider Trading
Apr 18, 2024	SC 13D/A	13D - Major Acquisition
Apr 17, 2024	144	Notice of Insider Sale Intent
Apr 11, 2024	S-8	Employee Benefits Plan
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 01, 2024	144	Notice of Insider Sale Intent
Apr 01, 2024	4	Insider Trading
Apr 01, 2024	144	Notice of Insider Sale Intent
Mar 28, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Stoke Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	38.7B	6.8B	-1.66%	-28.18%	-8.22	5.66	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.2B	1.8B	-2.46%	-28.84%	-41.3	9.94	76.23%	61.08%
BMRN	16.7B	2.4B	4.57%	-8.46%	99.75	6.91	15.42%	18.43%
INCY	11.8B	3.7B	-10.11%	-29.11%	19.67	3.18	8.87%	75.42%
MID-CAP
APLS	5.7B	396.6M	-14.37%	-42.33%	-10.84	14.45	425.83%	18.94%
BBIO	4.4B	-	-13.59%	50.21%	-6.66	60.35	54.84%	-34.79%
AXSM	3.2B	270.6M	-13.81%	-4.67%	-13.45	11.89	440.80%	-27.84%
ACAD	2.8B	726.4M	-9.91%	-15.82%	-45.22	3.82	40.45%	71.62%
ARWR	2.8B	240.7M	-20.67%	-25.33%	-9.32	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-10.64%	-8.42%	24.94	4.47	85.90%	-14.05%
NVAX	558.4M	983.7M	-17.39%	-51.52%	-1.02	0.57	-50.36%	17.16%
CRBP	409.4M	881.7K	-0.38%	387.14%	-9.18	466.16	-77.61%	-5.33%
INO	226.2M	4.9M	-10.29%	-2.81%	-1.67	46.49	-54.97%	51.71%
IBIO	6.0M	2.1M	59.81%	33.59%	-0.22	2.14	-13.45%	66.37%

Stoke Therapeutics Inc News

Latest updates

Stoke Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)								(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Revenue	-15.3%	3.00	3.00	4.00	5.00	3.00	3.00	3.00	3.00
Operating Expenses	6.0%	32.00	31.00	31.00	30.00	30.00	30.00	28.00	28.00
S&GA Expenses	3.3%	11.00	10.00	10.00	10.00	9.00	10.00	10.00	9.00
R&D Expenses	7.4%	22.00	20.00	21.00	20.00	21.00	20.00	18.00	18.00
Net Income	-9.8%	-26.96	-24.54	-30.65	-22.54	-25.65	-26.11	-24.65	-24.65
Net Income Margin	-23.5%	-11.92*	-9.66*	-8.31*	-6.80*	-8.15*	-	-	-
Free Cashflow	-18.3%	-20.88	-17.64	-22.64	-21.52	-22.78	-24.09	-20.61	32.00

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																				(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4
Assets	-4.8%	228	240	257	282	256	278	301	316	239	254	264	279	298	200	210	221	229	239	246	108
Current Assets	-6.4%	215	230	246	270	244	265	289	306	229	245	260	275	294	195	206	216	226	237	244	106
Cash Equivalents	0.8%	191	190	192	190	114	113	68.00	84.00	145	149	169	268	287	191	202	211	222	233	243	105
Net PPE	-6.3%	6.00	6.00	6.00	7.00	7.00	7.00	6.00	5.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	2.00	2.00	1.00
Liabilities	2.8%	69.00	67.00	67.00	68.00	71.00	73.00	77.00	76.00	21.00	16.00	9.00	6.00	12.00	7.00	7.00	6.00	4.00	5.00	5.00	2.00
Current Liabilities	22.3%	31.00	25.00	22.00	32.00	31.00	29.00	28.00	23.00	17.00	12.00	8.00	6.00	11.00	7.00	6.00	5.00	4.00	5.00	5.00	2.00
Shareholder's Equity	-7.8%	160	173	190	214	185	204	224	240	218	238	255	272	286	193	203	214	224	234	242	105
Retained Earnings	-7.2%	-401	-374	-350	-319	-297	-271	-245	-220	-196	-171	-149	-127	-110	-95.72	-82.03	-69.07	-58.03	-47.87	-39.27	-25.71
Additional Paid-In Capital	2.4%	561	548	541	534	483	477	471	461	414	409	404	400	396	288	285	283	282	282	281	131
Shares Outstanding	3.7%	46.00	44.00	44.00	44.00	39.00	39.00	38.00	37.00	37.00	37.00	37.00	37.00	-	-	-	-	-	-	-	-
Float	-	-	-	290	-	-	-	297	-	-	-	665	-	-	-	385	-	-	-	490	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-19.6%	-20,649	-17,262	-21,800	-21,356	-22,373	-22,056	-19,928	32,491	-16,258	-14,682	-15,831	-20,136	-10,931	-10,873	-9,646	-10,771	-10,201	-8,048	-6,274	-6,532	-
Share Based Compensation	-7.5%	6,058	6,552	6,760	5,887	5,790	5,926	6,163	4,975	4,686	4,614	4,452	2,698	1,580	1,785	1,649	754	712	731	298	181	-
Cashflow From Investing	1.1%	14,771	14,617	23,473	53,085	22,490	67,264	146	-135,782	11,797	-5,264	-82,755	-204	-90.00	-269	-81.00	-610	-569	-583	-392	-90.00	-
Cashflow From Financing	1206.6%	7,343	562	48.00	45,054	43.00	434	3,425	42,507	171	408	159	546	106,868	673	369	198	192	-1,000	150,638	-68.00	-

STOK Income Statement

2023-12-31

Consolidated statements of operations and comprehensive loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenue	$ 8,780	$ 12,405
Operating expenses:
Research and development	82,231	77,837
General and administrative	41,322	38,924
Total operating expenses	123,553	116,761
Loss from operations	(114,773)	(104,356)
Other income (expense):
Interest income (expense), net	9,908	3,122
Other income (expense), net	166	167
Total other income (expense)	10,074	3,289
Net loss	$ (104,699)	$ (101,067)
Net loss per share, basic	$ (2.38)	$ (2.60)
Net loss per share, diluted	$ (2.38)	$ (2.60)
Weighted-average common shares outstanding, basic	43,994,862	38,897,442
Weighted-average common shares outstanding, diluted	43,994,862	38,897,442
Comprehensive loss:
Net Income (Loss)	$ (104,699)	$ (101,067)
Other comprehensive loss:
Unrealized gain (loss) on marketable securities	1,151	(1,007)
Total other comprehensive gain (loss)	1,151	(1,007)
Comprehensive loss	$ (103,548)	$ (102,074)

STOK Balance Sheet

2023-12-31

Consolidated balance sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 191,442	$ 113,556
Marketable securities	9,952	116,039
Prepaid expenses	11,320	10,932
Other current assets	2,561	2,955
Interest receivable	64	588
Total current assets	215,339	244,070
Restricted cash	569	569
Operating lease right-of-use assets	6,611	4,753
Property and equipment, net	5,823	6,675
Total assets	228,342	256,067
Current liabilities:
Accounts payable	1,695	766
Accrued and other current liabilities	13,815	15,748
Deferred revenue - current portion	15,309	14,880
Total current liabilities	30,819	31,394
Deferred revenue - net of current portion	33,074	36,856
Other long term liabilities	4,884	2,968
Total long term liabilities	37,958	39,824
Total liabilities	68,777	71,218
Commitments and contingencies (Note 7)
Stockholders’ equity
Common stock, par value of $0.0001 per share; 300,000,000 shares authorized, 45,918,233 and 39,439,575 shares issued and outstanding as of December 31, 2023 and 2022, respectively	5	4
Additional paid-in capital	561,433	483,170
Accumulated other comprehensive loss	(24)	(1,175)
Accumulated deficit	(401,849)	(297,150)
Total stockholders’ equity	159,565	184,849
Total liabilities and stockholders’ equity	$ 228,342	$ 256,067

About Stoke Therapeutics Inc

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company is also developing STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is based in Bedford, Massachusetts.

CEO	Dr. Edward M. Kaye M.D., Ph.D.
WEBSITE	stoketherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	117

Stoke Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Stoke Therapeutics Inc? What does STOK stand for in stocks?

STOK is the stock ticker symbol of Stoke Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Stoke Therapeutics Inc (STOK)?

As of Fri Apr 19 2024, market cap of Stoke Therapeutics Inc is 557.96 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of STOK stock?

You can check STOK's fair value in chart for subscribers.

What is the fair value of STOK stock?

You can check STOK's fair value in chart for subscribers. The fair value of Stoke Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Stoke Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for STOK so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Stoke Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether STOK is over valued or under valued. Whether Stoke Therapeutics Inc is cheap or expensive depends on the assumptions which impact Stoke Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for STOK.

What is Stoke Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, STOK's PE ratio (Price to Earnings) is -5.33 and Price to Sales (PS) ratio is 63.55. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. STOK PE ratio will change depending on the future growth rate expectations of investors.